Stryker Corp (SYK) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Stryker Corporation is a global leader in medical technologies operating in two reportable segments: MedSurg and Neurotechnology and Orthopaedics. The quarter was defined by the completion of the Inari Medical, Inc. acquisition and the divestiture of the U.S. Spinal Implants business.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $5,866 million | $5,243 million |
| Gross Profit | $3,744 million | $3,333 million |
| Operating Income | $837 million | $972 million |
| Net Earnings | $654 million | $788 million |
| Diluted EPS | $1.69 | $2.05 |
| Operating Margin | 14.3% | 18.5% |
| Cash from Operations | $250 million | $204 million |
| Total Debt | $16,781 million | $13,597 million |
| Cash & Equivalents | $2,320 million | $3,652 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.9% year-over-year, driven by 10.1% organic growth in constant currency. MedSurg and Neurotechnology sales grew 13.4%, while Orthopaedics grew 9.7%.
- Profitability Decline: GAAP operating income decreased 13.9% and net earnings decreased 17.0%. This decline is primarily attributed to significant one-time charges related to the Inari acquisition and asset impairments.
- Acquisition Impact: The company acquired Inari Medical for $4.745 billion in cash. This resulted in $185 million in acquisition and integration-related charges and a $139 million charge for share-based awards vesting upon acquisition.
- Impairments: Goodwill and other impairments totaled $35 million, largely due to a $33 million charge to write down the U.S. Spinal Implants business held for sale.
- Debt Issuance: Total debt increased by approximately $3.2 billion due to the issuance of $3 billion in new senior unsecured notes to fund the Inari acquisition.
Guidance, Outlook, and Risks
- Adjusted Performance: Management highlights adjusted operating income margin of 22.9% (up 100 basis points) and adjusted diluted EPS of $2.84 (up 13.6%), excluding acquisition costs, impairments, and other special items.
- Divestiture: The company completed the sale of its U.S. Spinal Implants business in April 2025 (subsequent event). A binding offer exists for international markets.
- Macro Risks: Management notes risks from new U.S. tariffs on goods from China and the EU, which could increase product costs or impact demand. Geopolitical instability and inflation remain concerns.
- Legal & Regulatory: The company is cooperating with investigations regarding potential Foreign Corrupt Practices Act (FCPA) violations; the DOJ inquiry was closed in April 2025 without further action. Product liability accruals stand at $169 million.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost realization for integrating Inari Medical, specifically the $139 million stock compensation charge and future amortization of intangibles ($561 million expected for remainder of 2025).
- Spinal Implants Divestiture: Confirm the final sale price and timing for the international Spinal Implants business, as the U.S. portion has already been sold.
- Tariff Exposure: Assess the specific impact of new U.S. tariffs on the cost of goods sold for products manufactured in China or the EU.
- Debt Service: Review the interest expense impact of the new $3 billion debt issuance (rates ranging from 4.55% to 5.20%) on future cash flows.
- Product Recalls: Monitor the status of accruals for Rejuvenate, ABG II, and LFIT hip product recalls, as final costs may differ from the current $169 million estimate.